Cutera
Trial Pipeline
A Post Market Device Study for the Treatment of Acne
NCT06469398
enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars
NCT03284333
Performance Evaluation of the truSculpt Radiofrequency Device for Lipolysis of Abdominal Fat
NCT03433417
Feasibility Study of the TruSculpt Radiofrequency Device
NCT03018587
Study of a Novel Laser for Skin Rejuvenation
NCT02910492
Pilot Study of Multi-wavelength Laser for Tattoo Removal
NCT03290547
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
NCT02268474
Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair
NCT01912950
The Trusculpt (Radio Frequency) Device For Thigh Circumference Reduction
NCT01665118
Therapeutic Areas
What the Pipeline for Cutera Shows
According to the ClinicalTrials.gov registry, Cutera is linked to 9 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 8 are already marked complete, representing roughly 89% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Cutera reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Cutera is Body Fat with 2 linked trials, and 8 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.